{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019717","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.321533+00:00","generated_at":"2026-06-07T14:42:15.011101+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Capricor Phase 3 HOPE-3 trial of CAP-1002 in DMD passes interim futility analysis; milestone payment triggered","bullets":["Positive interim futility analysis from DSMB; trial to continue as planned.","Triggers first milestone payment under U.S. agreement with Nippon Shinyaku.","HOPE-3 Cohort A enrollment complete; topline data expected Q4 2024.","Company plans to request FDA meeting in Q1 2024 for expedited approval pathways.","Cohort B enrollment initiated; ~102 subjects total across both cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019717","json":"https://secwatch.observer/filing/0001558370-23-019717.json","markdown":"https://secwatch.observer/filing/0001558370-23-019717.md","text":"https://secwatch.observer/filing/0001558370-23-019717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023019717/0001558370-23-019717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023019717/capr-20231211x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:42:15.011101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}